FDA targets January for Pfizer COVID-19 vaccine approval decision

Fox Business Flash top headlines for July 16

Check out what’s clicking on FoxBusiness.com.

The Food and Drug Administration (FDA) will weigh full approval for the Pfizer-BioNTech COVID-19 vaccine in people aged 16 and older by January, the companies announced Friday.

TickerSecurityLastChangeChange %
PFEPFIZER INC.40.24+0.15+0.39%
BNTXBIONTECH SE231.06+9.98+4.51%

The FDA granted a "priority review" designation for the companies’ Biologics License Application (BLA) completed in May, which included late-stage trial data on safety and efficacy up to six months post-second dose.

The FDA has not yet approved any COVID-19 vaccine, but has given emergency use authorization (EUA) to vaccines developed by Pfizer-BioNTech, Moderna and Johnson & Johnson.

The FDA did not respond to FOX Business' request for comment at the time of publication.

This is a developing story. Check back for updates.

Source: Read Full Article